<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1682-0037</journal-id>
<journal-title><![CDATA[Revista Cubana de Angiología y Cirugía Vascular]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Angiol Cir Vasc]]></abbrev-journal-title>
<issn>1682-0037</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1682-00372019000100003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evolución de las úlceras de pie diabético con el tratamiento mixto de Heberprot-P® y ozonoterapia]]></article-title>
<article-title xml:lang="en"><![CDATA[Evolution of diabetic foot ulcers with the mixed treatment of Heberprot-P® and ozone therapy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fabelo Martínez]]></surname>
<given-names><![CDATA[Amirelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa Martínez]]></surname>
<given-names><![CDATA[Alain]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valdés Pérez]]></surname>
<given-names><![CDATA[Calixto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Leonard]]></surname>
<given-names><![CDATA[Damaris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez López]]></surname>
<given-names><![CDATA[Adanay Álvarez]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Angiología y Cirugía Vascular  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1682-00372019000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1682-00372019000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1682-00372019000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  El Heberprot-P® es un medicamento novedoso y único, prescrito para los pacientes con úlcera del pie diabético. El factor de crecimiento humano recombinante que contiene este fármaco induce el crecimiento de tejido de granulación útil. La ozonoterapia tiene propiedades como oxigenante, antioxidante, inmunomodulador, regenerador, antiinflamatorio y germicida y se utiliza para la desinfección de heridas desde la Primera Guerra Mundial.  Objetivo: Determinar la evolución de las úlceras del pie diabético con el tratamiento mixto de Heberprot-P® y ozonoterapia.  Métodos: Se realizó un estudio retrospectivo y descriptivo en todos los pacientes ingresados en el Instituto Nacional de Angiología y Cirugía Vascular con el diagnóstico de diabetes mellitus y úlcera de pie diabético que recibieron tratamiento mixto de Heberprot-P® y ozonoterapia. El período de estudio osciló de enero de 2016 hasta enero de 2017. Las variables estudiadas fueron: sexo, edad, tipo de diabetes, estadía hospitalaria, necesidad de ser reintervenido, tiempo de granulación y respuesta al tratamiento.  Resultados:  Se encontró que los pacientes tratados con el Heberprot-p® y ozonoterapia tuvieron una buena respuesta al tratamiento (60,5 %), un tiempo de granulación entre 2 y 4 semanas (55,6 %) con predominio de la estadía hospitalaria de 11 a 21 días.  Conclusiones:  Los pacientes con el tratamiento mixto de Heberprot-P® y ozonoterapia tienen una respuesta muy favorable.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Heberprot-P® is a novel and unique medication, prescribed for patients with diabetic foot ulcer. It is based on recombinant human growth factor that induces the growth of useful granulation tissue. The properties as oxygenating, antioxidant, immunomodulator, regenerator, anti-inflammatory and germicide of ozone therapy are used for the disinfection of wounds since the First World War.  Objective:  To determine the evolution of diabetic foot ulcers with the mixed treatment of Heberprot-P® and ozone therapy.  Methods:  A retrospective and descriptive study was conducted in all patients admitted to the National Institute of Angiology and Vascular Surgery (INACV) with the diagnosis of Diabetes Mellitus and diabetic foot ulcer who received mixed treatment of Heberprot-P® and ozone therapy. The study period ranged from January 2016 to January 2017. The studied variables were: sex, age, type of diabetes, hospital stay, need to be reoperated, granulation time and response to the treatment.  Results:  It was found that the highest percentage of patients who used the mixed treatment of Heberprot-P® and ozone therapy had a good response to treatment (60.5 %) and a granulation time between 2 and 4 weeks (55.6 %); and a hospital stay from 11 to 21 days.  Conclusions:  Patients with the mixed treatment of Heberprot-P® and ozone therapy have a very favorable response.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[úlcera del pie diabético]]></kwd>
<kwd lng="es"><![CDATA[Heberprot-P®]]></kwd>
<kwd lng="es"><![CDATA[ozonoterapia]]></kwd>
<kwd lng="en"><![CDATA[diabetic foot ulcer]]></kwd>
<kwd lng="en"><![CDATA[ozone therapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>International Diabetes Federation</collab>
<source><![CDATA[International Diabetes Federation. Diabetes Atlas]]></source>
<year>2015</year>
<edition>7ma</edition>
<publisher-loc><![CDATA[Brussels, Belgium ]]></publisher-loc>
<publisher-name><![CDATA[IDF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Guía de Práctica Clínica (GPC) de Diabetes mellitus tipo 2]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[Dirección Nacional de Normatización]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendoza Romo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Padrón Salas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cossío Torres]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Soria Orozco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia mundial de la diabetes mellitus tipo II y su relación con el índice de desarrollo humano]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2017</year>
<volume>41</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública. Dirección Nacional de Registros Médicos y Estadísticas de Salud</collab>
<source><![CDATA[Anuario estadístico de salud 2017]]></source>
<year>2017</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdaguer Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencias en el tratamiento con Heberprot-P(r) en pacientes con pie diabético.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Muguercia Silva]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala Lafargue]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bertrán Bahades]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada Ladoy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[MEDISAN]]></source>
<year>2017</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1012-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence</collab>
<source><![CDATA[Diabetic foot problems: prevention and management]]></source>
<year>2015</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[National Institute for Health and Clinical Excellence]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Damas-Casani]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clasificación de pie en riesgo de ulceración según el Sistema IWGDF y factores asociados en pacientes con diabetes mellitus tipo 2 de un hospital]]></article-title>
<source><![CDATA[Rev Med Hered]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<source><![CDATA[Manual de promotores Heberprot-P. Una herramienta imprescindible para los hebepropistas]]></source>
<year>2015</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Elfos Scientiae]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillo Tirado]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica en el pie diabético]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fernández López]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo Tirado]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Archivos de medicina]]></source>
<year>2001</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llanes Barrios]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta Ravelo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Díaz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Melgarejo Rivero]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Torres Zaldivar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atención multidisciplinaria con terapia avanzada y de recurso a pacientes con pie diabético en Mayabeque]]></article-title>
<source><![CDATA[Rev Cubana de Angiol Cir Vasc]]></source>
<year>2015</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>139-53</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez Duarte]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beneficios de la intervención con ozonoterapia en pacientes con pie diabético neuroinfeccioso]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hernández Carretero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arpajón Peña]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2014</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Sánchez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La ozonoterapia gana evidencias científicas en el campo clínico editorial]]></article-title>
<source><![CDATA[Rev Cubana Farm]]></source>
<year>2013</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto modulador de la ozonoterapia sobre la actividad del sistema inmune]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Macías]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Menéndez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Hematol Inmunol]]></source>
<year>2012</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bocci]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Scientific and medical aspects of ozone therapy State of the art]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>2006</year>
<volume>37</volume>
<page-range>425-35</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bladinieres-Camara]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Uhthoff-Brito]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alcalá-Duran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Anaya-Prado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lara-Ramírez]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pie diabético neuroisquémico tratado con ozonoterapia]]></article-title>
<source><![CDATA[Cirujano General]]></source>
<year>2015</year>
<volume>37</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>44-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Calvagno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tolstano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carrio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bullo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de úlceras severas de pie diabético con factor de crecimiento epidérmico recombinante (Heberprot- P(r)) Análisis retrospectivo de los resultados. obtenidos en Argentina]]></article-title>
<source><![CDATA[Rev Argentina Cirug Cardiovasc]]></source>
<year>2012</year>
<numero>4</numero>
<issue>4</issue>
<page-range>153-62</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivero]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencias del Programa de atención integral a pacientes con pie diabético en el estado Zulia, Venezuela]]></article-title>
<source><![CDATA[Biotecnología Aplicada]]></source>
<year>2009</year>
<volume>27</volume>
<page-range>101-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Saura]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Yera-Alos]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González Díaz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[del Río Martín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Adv Pharmacoepidemiol Drug Saf]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>2</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yera]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Debesa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad y seguridad del Heberprot-P en el tratamiento durante la etapa de poscomercialización en Cuba]]></article-title>
<source><![CDATA[Biotecnología Aplicada]]></source>
<year>2010</year>
<volume>27</volume>
<page-range>124-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Acosta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Calaña González Posada]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Marrero Rodríguez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[López Fernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución clínica del tratamiento en el pie diabético con Heberprot-P o con el método convencional]]></article-title>
<source><![CDATA[Rev Cubana de Angiol y Cir Vasc]]></source>
<year>2011</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández Rivero]]></surname>
<given-names><![CDATA[M J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heberprot-P, una terapia eficaz en la prevención de la amputación en el pie diabético]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Llanes Barrios J]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta Lapera D]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana de Angiol Cir Vasc]]></source>
<year>2009</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escobar Amarales]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El Heberprot-P en el tratamiento de úlceras del pie diabético]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Torres Romo]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Escalante Padrón]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Arch Méd Camagüey]]></source>
<year>2014</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Sánchez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ozone Therapy and Its Scientific Foundation]]></article-title>
<source><![CDATA[Rev Esp Ozonoterapia]]></source>
<year>2012</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>63-98</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kontorchnikova]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Malesnikov]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Sanchez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Re]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía para el uso médico del ozono: fundamentos terapéuticos e indicaciones]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Asociación Española de Profesionales Médicos en Ozonoterapia (AEPROMO)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bocci]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Borelli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Travagli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Zanardi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ozone paradox ozone is a strong oxidant as well as a medical drug]]></article-title>
<source><![CDATA[Med Res Rev]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>646-82</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto modulador de la ozonoterapia sobre la actividad del sistema inmune]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Macías]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Menéndez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Hematol Inmunol]]></source>
<year>2012</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Travagli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Zanardi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bernini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nepi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tenori]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bocci]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of ozone blood treatment on the metabolite profile of human blood]]></article-title>
<source><![CDATA[Int J Toxicol]]></source>
<year>2010</year>
<volume>29</volume>
<page-range>165-74</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio clínico de eficacia y tolerancia del ozono en afecciones venolinfaticas]]></article-title>
<source><![CDATA[Rev Española Ozonoterapia]]></source>
<year>2016</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-50</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de úlcera en pie diabético con Ozono de sonda fría. Reporte de un caso]]></article-title>
<source><![CDATA[Rev Española Ozonoterapia]]></source>
<year>2016</year>
<volume>6</volume>
<numero>¡</numero>
<issue>¡</issue>
<page-range>217-22</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
